Efficacy of Liposomal Nystatin in a Rabbit Model of Cryptococcal Meningitis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Animals
2.2. Organism
2.3. Inoculations and CSF Collections
2.4. Measurement of Nystatin Levels
2.5. Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Denning, D.W. Global incidence and mortality of severe fungal disease. Lancet Infect. Dis. 2024, 24, e428–e438. [Google Scholar] [CrossRef] [PubMed]
- Milefchik, E.; Leal, M.A.; Haubrich, R.; Bozzette, S.A.; Tilles, J.G.; Leedom, J.M.; McCutchan, J.A.; Larsen, R.A. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med. Mycol. 2008, 46, 393–395. [Google Scholar] [CrossRef]
- Lalloo, U.G.; Komarow, L.; Aberg, J.A.; Clifford, D.B.; Hogg, E.; McKhann, A.; Bukuru, A.; Lagat, D.; Pillay, S.; Mave, V.; et al. Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group. PLoS ONE 2023, 18, e0281580. [Google Scholar] [CrossRef]
- Jarvis, J.N.; Lawrence, D.S.; Meya, D.B.; Kagimu, E.; Kasibante, J.; Mpoza, E.; Rutakingirwa, M.K.; Ssebambulidde, K.; Tugume, L.; Rhein, J.; et al. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. N. Engl. J. Med. 2022, 386, 1109–1120. [Google Scholar] [CrossRef]
- Johnson, E.M.; Ojwang, J.O.; Szekely, A.; Wallace, T.L.; Warnock, D.W. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob. Agents Chemother. 1998, 42, 1412–1416. [Google Scholar] [CrossRef] [PubMed]
- Ghielmetti, G.; Bruzzese, T.; Bianchi, C.; Recusani, F. Relationship between acute toxicity in mice and polymorphic forms of polyene antibiotics. J. Pharm. Sci. 1976, 65, 905–907. [Google Scholar] [CrossRef]
- Mehta, R.T.; Hopfer, R.L.; Gunner, L.A.; Juliano, R.L.; Lopez-Berestein, G. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. 1987, 31, 1897–1900. [Google Scholar] [CrossRef]
- Mehta, R.T.; Hopfer, R.L.; McQueen, T.; Juliano, R.L.; Lopez-Berestein, G. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. 1987, 31, 1901–1903. [Google Scholar] [CrossRef] [PubMed]
- Wallace, T.L.; Paetznick, V.; Cossum, P.A.; Lopez-Berestein, G.; Rex, J.H.; Anaissie, E. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob. Agents Chemother. 1997, 41, 2238–2243. [Google Scholar] [CrossRef]
- Groll, A.H.; Gonzalez, C.E.; Giri, N.; Kligys, K.; Love, W.; Peter, J.; Feuerstein, E.; Bacher, J.; Piscitelli, S.C.; Walsh, T.J. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: Efficacy, safety and non-compartmental pharmacokinetics. J. Antimicrob. Chemother. 1999, 43, 95–103. [Google Scholar] [CrossRef]
- Groll, A.H.; Petraitis, V.; Petraitiene, R.; Field-Ridley, A.; Calendario, M.; Bacher, J.; Piscitelli, S.C.; Walsh, T.J. Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 1999, 43, 2463–2467. [Google Scholar] [CrossRef] [PubMed]
- Aronex Pharmaceuticals, I. Form 10-K, Annual Report Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934. 2000. Available online: https://www.sec.gov/Archives/edgar/data/854691/000095012901001852/h85707e10-k.txt (accessed on 1 June 2024).
- Groll, A.H.; Mickiene, D.; Werner, K.; Piscitelli, S.C.; Walsh, T.J. High-performance liquid chromatographic determination of liposomal nystatin in plasma and tissues for pharmacokinetic and tissue distribution studies. J. Chromatogr. B Biomed. Sci. Appl. 1999, 735, 51–62. [Google Scholar] [CrossRef] [PubMed]
- Groll, A.H.; Mickiene, D.; Werner, K.; Petraitiene, R.; Petraitis, V.; Calendario, M.; Field-Ridley, A.; Crisp, J.; Piscitelli, S.C.; Walsh, T.J. Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits. Antimicrob. Agents Chemother. 2000, 44, 950–957. [Google Scholar] [CrossRef] [PubMed]
- Giamberardino, C.D.; Schell, W.A.; Tenor, J.L.; Toffaletti, D.L.; Palmucci, J.R.; Marius, C.; Boua, J.K.; Soltow, Q.; Mansbach, R.; Moseley, M.A.; et al. Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis. mBio 2022, 13, e0234722. [Google Scholar] [CrossRef] [PubMed]
- Offner, F.; Krcmery, V.; Boogaerts, M.; Doyen, C.; Engelhard, D.; Ribaud, P.; Cordonnier, C.; de Pauw, B.; Durrant, S.; Marie, J.P.; et al. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob. Agents Chemother. 2004, 48, 4808–4812. [Google Scholar] [CrossRef] [PubMed]
- Krupova, Y.; Mistrik, M.; Bojtarova, E.; Sejnova, D.; Ilavska, I.; Krcmery, V., Jr. Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients. Support. Care Cancer 2001, 9, 209–210. [Google Scholar] [CrossRef] [PubMed]
- Lestner, J.; McEntee, L.; Johnson, A.; Livermore, J.; Whalley, S.; Schwartz, J.; Perfect, J.R.; Harrison, T.; Hope, W. Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. Antimicrob. Agents Chemother. 2017, 61, e00090-17. [Google Scholar] [CrossRef] [PubMed]
- Perfect, J.R.; Durack, D.T. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob. Agents Chemother. 1985, 28, 751–755. [Google Scholar] [CrossRef]
- Perfect, J.R.; Granger, D.L.; Durack, D.T. Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells. J. Infect. Dis. 1987, 156, 316–323. [Google Scholar] [CrossRef]
- Sousa, F.; Nascimento, C.; Ferreira, D.; Reis, S.; Costa, P. Reviving the interest in the versatile drug nystatin: A multitude of strategies to increase its potential as an effective and safe antifungal agent. Adv. Drug Deliv. Rev. 2023, 199, 114969. [Google Scholar] [CrossRef]
- Perfect, J.R. The antifungal pipeline: A reality check. Nat. Rev. Drug Discov. 2017, 16, 603–616. [Google Scholar] [CrossRef] [PubMed]
- Nasti, T.H.; Khan, M.A.; Owais, M. Enhanced efficacy of pH-sensitive nystatin liposomes against Cryptococcus neoformans in murine model. J. Antimicrob. Chemother. 2006, 57, 349–352. [Google Scholar] [CrossRef] [PubMed]
- Molloy, S.F.; Kanyama, C.; Heyderman, R.S.; Loyse, A.; Kouanfack, C.; Chanda, D.; Mfinanga, S.; Temfack, E.; Lakhi, S.; Lesikari, S.; et al. Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N. Engl. J. Med. 2018, 378, 1004–1017. [Google Scholar] [CrossRef] [PubMed]
Experimental Group | Number of Rabbits | Number of CSF Data Points | Slope (EFA) (log10 CFU/mL/day) | SE | Lower Limit 95% CI | Upper Limit 95% CI |
---|---|---|---|---|---|---|
control | 6 | 24 | 0.17 | 0.05 | 0.08 | 0.26 |
amphotericin B, 1 mg/kg | 6 | 21 | −0.36 | 0.04 | −0.45 | −0.28 |
liposomal nystatin, 3 mg/kg | 6 | 20 | 0.08 | 0.05 | −0.02 | 0.17 |
liposomal nystatin, 8 mg/kg | 7 | 20 | 0.11 | 0.05 | 0.01 | 0.21 |
Group | Time | CSF (mean ± SD) n * | Plasma (mean ± SD) | Brain (mean ± SD) |
---|---|---|---|---|
liposomal nystatin, 3 mg/kg | 0.5 | NA | 11.38 (±2.1) n = 4 | NA |
liposomal nystatin, 8 mg/kg | 4 | NA | 24.89 (±7.93) n = 3 | NA |
liposomal nystatin, 3 mg/kg | 24 | 0 (+0) n = 6 | 0.01 (±0.02) n = 4 | 0.04 (±0) n = 2 |
liposomal nystatin, 8 mg/kg | 24 | 0.02 (+0.03) n = 5 | 0.18 (±0.09) n = 3 | 1.67 (±0.88) n = 3 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Giamberardino, C.D.; Schell, W.A.; Tenor, J.L.; Toffaletti, D.L.; Perfect, J.R. Efficacy of Liposomal Nystatin in a Rabbit Model of Cryptococcal Meningitis. J. Fungi 2024, 10, 520. https://doi.org/10.3390/jof10080520
Giamberardino CD, Schell WA, Tenor JL, Toffaletti DL, Perfect JR. Efficacy of Liposomal Nystatin in a Rabbit Model of Cryptococcal Meningitis. Journal of Fungi. 2024; 10(8):520. https://doi.org/10.3390/jof10080520
Chicago/Turabian StyleGiamberardino, Charles D., Wiley A. Schell, Jennifer L. Tenor, Dena L. Toffaletti, and John R. Perfect. 2024. "Efficacy of Liposomal Nystatin in a Rabbit Model of Cryptococcal Meningitis" Journal of Fungi 10, no. 8: 520. https://doi.org/10.3390/jof10080520
APA StyleGiamberardino, C. D., Schell, W. A., Tenor, J. L., Toffaletti, D. L., & Perfect, J. R. (2024). Efficacy of Liposomal Nystatin in a Rabbit Model of Cryptococcal Meningitis. Journal of Fungi, 10(8), 520. https://doi.org/10.3390/jof10080520